Stockreport

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]

Immuneering Corporation - Class A  (IMRX) 
PDF IMRX's combination nearly doubles standard-of-care 12-month OS (64% vs. 35%), with a favorable safety profile and regulatory alignment for phase 3 initiation mid-2026. [Read more]